Parkinson’s disease is a brain disorder that affects movement, making everyday tasks difficult for nearly one million people ...

Nicole LaBolle initially dismissed her shaking as something fairly common before facing a Parkinson's diagnosis at 28 ...

People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.

The Google cofounder has donated more than $1.5 billion to Parkinson’s research. Now, as he takes on autism, he’s also ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Parkinson's is a brain condition which is responsible for uncontrolled movements. It causes difficulty in talking, walking, ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...

A Colorado Springs family hopes to win what they believe would be a landmark legal verdict by proving to jurors next month ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

Now, a new study from Renmin Hospital of Wuhan University provides strong evidence that kidney failure may also contribute to the development of Parkinson’s disease by triggering the spread of ...